Showing results (481-490 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|October 1, 1995
Glutathione S transferase-theta (GSTT1) genetic polymorphism among Chinese, Malays and Indians in SingaporeE J Lee, J Y Wong, P N Yeoh, et al.Pharmacogenetics|December 1, 1995
Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in CaucasiansM Pirmohamed, N R Kitteringham, L J Quest, et al.Pharmacogenetics|December 1, 1995
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotypeM Chang, M L Dahl, G Tybring, et al.Pharmacogenetics|December 1, 1995
Fetal mouse susceptibility to transplacental carcinogenesis: differential influence of Ah receptor phenotype on effects of 3-methylcholanthrene, 12-dimethylbenz[a]anthracene, and benzo[a]pyreneL M Anderson, S Ruskie, J Carter, et al.Pharmacogenetics|April 1, 1993
Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizersL S Chen, T Yasumori, Y Yamazoe, et al.Pharmacogenetics|August 1, 1995
Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori populationS Wanwimolruk, E L Pratt, J R Denton, et al.Pharmacogenetics|August 1, 1995
Lung cancer and mutations at the polymorphic NAT2 gene locusC Martínez, J A Agúndez, M Olivera, et al.Pharmacogenetics|November 24, 1998
Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liverT J Yang, Y Sai, K W Krausz, et al.Pharmacogenetics|November 24, 1998
Predisposition towards urolithiasis associated with the NQO1 null-alleleW A Schulz, A Krummeck, I Rösinger, et al.Pharmacogenetics|January 26, 1999
CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los AngelesJ B Leathart, S J London, A Steward, et al.Pageof 83